The Cancer Consortium is organized into 13 highly collaborative research programs that are discipline or disease specific. The Cancer Consortium brings together over 400 faculty with research interests in basic, clinical/translational, public health sciences and global health.
Program Head — Jonathan Cooper, Ph.D.
Associate Program Head — Susan Biggins, Ph.D.
Basic Sciences is composed of faculty who study basic mechanisms of molecular, cellular and developmental biology. Faculty members in this program have strong interactions with nearly all programs in the Consortium and research projects have direct impact on disease-related research in leukemia, lymphoma, cervical, breast, prostate, gastrointestinal, brain and lung cancers.
Biostatistics and Biomathematics
Co-Program Heads — Steve Self, Ph.D., and Charles Kooperberg, Ph.D.
This program carries out research in statistical methodology and mathematical models of carcinogenesis, and provides statistical support for clinical trials, prevention trials, and other research programs in the Consortium. Its research endeavors directly impact disease-related research in leukemia, lymphoma, breast, prostate, gastrointestinal, brain cancers and HIV/AIDS.
Co-Program Heads — Janet Eary, M.D. and Connie Lehman, M.D., Ph.D.
Associate Program Head — Ken Krohn, Ph.D.
This program, formerly the Molecular Imaging program, has evolved to include all of the Consortium's imaging faculty. The goals of the Cancer Imaging Program are to further understanding of the biology of cancer and to provide earlier detection, more accurate diagnosis and improved evaluation of response to treatments through the development of new biologically relevant agents and the application of imaging modalities including PET, MRI, ultrasound and optical imaging. Disease interests of the program faculty include leukemia, lymphoma, breast, prostate, brain, lung, gynecologic and sarcoma cancers.
Program Head — Polly Newcomb, Ph.D., M.P.H.
Associate Program Heads — Alan Kristal, Dr.PH
The goals of this program are to understand cancer etiology, identify risk factors, and carry out population-based intervention studies that reduce cancer morbidity and mortality. Its research activities directly impact disease-related research in ovarian, breast, prostate, gastrointestinal, cervical and lung cancer.
Program Head — Fred Appelbaum, M.D.
Associate Program Head — Effie Petersdorf, M.D.
This program is focused on improvements in bone marrow and stem cell transplantation as a treatment modality, primarily for cancers of the blood like leukemia and lymphoma.
Gastrointestinal Cancer Etiology, Prevention and Early Detection
Co-Program Heads — Bill Grady, M.D. and Ray Yeung, M.D.
Co-Associate Program Heads — Sunil Hingorani, M.D., Ph.D and Cornelia Ulrich, Ph.D.
The goals of the GI Cancer program are to conduct multidisciplinary research in the biology, epidemiology, prevention, and screening and early intervention of upper GI cancers, hepatitis C virus and liver cancer, pancreas cancer, H. pylori and stomach cancer and colorectal cancers
Program Head — Kathi Malone, Ph.D.
The goals of this program are to identify the factors that influence the risk of developing cancer, discover the impact that these factors have on cancer incidence in the human population, and uncover the causes that influence a patient's survival and quality of life. Research in this program is directly involved in ovarian, breast, prostate, gastrointestinal, cervical, hematologic and oral cancers.
Genome Instability and Mutagenesis
Program Head — Ray Monnat, M.D.
Associate Program Head — Larry Loeb, Ph.D.
This program is focused on developing a deeper understanding of the role of heritable and acquired genome instability in cancer. The aim is to achieve a mechanistic understanding of genetic and environmental determinants of human genome stability, and the role of genome instability in tumor pathogenesis and progression.
Immunology and Vaccine Development
Co-Program Heads — Philip Greenberg, M.D. and Julie McElrath, M.D., Ph.D.
Associate Program Head — Stanley Riddell, M.D. and Michael Jensen, M.D.
Program goals include: studying fundamental immunologic mechanisms relevant to the development of strategies to modulate the immune system to enhance opportunities; studying fundamental immunologic mechanisms relevant to the modulation of the innate immune system for the purpose of enhancing immune responses to vaccine immunogens; and performing preclinical studies and clinical trials to develop vaccines for the prevention of life-threatening infections and treatment of cancer.
Prostate Cancer Research
Program Head — Pete Nelson, M.D. and Janet Stanford, Ph.D.
Associate Program Head — Paul Lange, M.D.
This program is focused on advancing scientific knowledge that will lead to a reduction in the morbidity and mortality attributed to this common and complex disease and to an improvement in patients' quality and quantity of life. The program encompasses basic, population, and clinical research, and collaborates strongly with the discipline-based programs Basic Sciences, Biostatistics, Cancer Imaging, Cancer Prevention and Epidemiology.
Stem/Progenitor Cell Biology
Co-Program Heads - Anthony Blau, M.D. and Beverly Torok-Storb, Ph.D.
Co-Associate Program Heads - David Emery, Ph.D. and Shelly Heimfeld, Ph.D.
The Stem/Progenitor Cell Biology program is new with this CCSG submission. The program's goals are twofold: to 1) identify molecular events that are responsible for, and/or a marker of, stem cell self replication, differentiation, and malignant transformation; and 2) identify molecular interventions that can control stem cell fate and abrogate the aberrant signaling that occurs in cancer stem cells. Research includes basic molecular and cellular biology; the application of basic research to the development of preclinical models; and the translation of these preclinical studies to clinical protocols. Basic studies utilize adult and embryonic sources of normal or malignant stem cells from humans, mice, dogs, and nonhuman primates.
Transplantation Biology Program
Program Head — Rainer Storb, M.D.
Associate Program Head — Paul Martin, M.D.
This program combines basic and translational research in immunogenetics, the biology of blood and marrow stem cell grafting, and gene therapy for treatment of patients with cancer, autoimmune diseases, and acquired defects and genetic diseases of the hematopoietic system and muscle.
Co-Program Heads - Peggy Porter, M.D. and Nicole Urban, Sc.D.
Co-Associate Program Heads - Julie Gralow, M.D. and Barbara Goff, M.D.
The Women's Cancer Program focuses on reducing the incidence and subsequent mortality of breast and gynecologic cancers. Interdisciplinary research is conducted to improve cancer prevention, detection, diagnosis and treatment. The current program is an effective, on-going collaboration of Fred Hutchinson Cancer Research Center and University of Washington faculty who interact strongly with discipline-based programs of Basic Sciences, Biostatistics, Cancer Imaging, Cancer Prevention and Epidemiology.